{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T11:35:26Z","timestamp":1794569726682,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T00:00:00Z","timestamp":1523836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1038\/s41591-018-0006-x","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T04:33:11Z","timestamp":1523853191000},"page":"572-579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":484,"title":["Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas"],"prefix":"10.1038","volume":"24","author":[{"given":"Christopher W.","family":"Mount","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbie G.","family":"Majzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shree","family":"Sundaresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan P.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena","family":"Kadapakkam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Haile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louai","family":"Labanieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Hulleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamelyn J.","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skyler P.","family":"Rietberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3547-237X","authenticated-orcid":false,"given":"Michelle","family":"Monje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6323-4304","authenticated-orcid":false,"given":"Crystal L.","family":"Mackall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,16]]},"reference":[{"key":"6_CR1","doi-asserted-by":"publisher","first-page":"6219","DOI":"10.1158\/0008-5472.CAN-13-1491","volume":"73","author":"BS Paugh","year":"2013","unstructured":"Paugh, B. S. et al. Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. Cancer Res. 73, 6219\u20136229 (2013).","journal-title":"Cancer Res."},{"key":"6_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/ng.1102","volume":"44","author":"G Wu","year":"2012","unstructured":"Wu, G. et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat. Genet. 44, 251\u2013253 (2012).","journal-title":"Nat. Genet."},{"key":"6_CR3","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/ng.2936","volume":"46","author":"P Buczkowicz","year":"2014","unstructured":"Buczkowicz, P. et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat. Genet. 46, 451\u2013456 (2014).","journal-title":"Nat. Genet."},{"key":"6_CR4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/ng.2925","volume":"46","author":"KR Taylor","year":"2014","unstructured":"Taylor, K. R. et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat. Genet. 46, 457\u2013461 (2014).","journal-title":"Nat. Genet."},{"key":"6_CR5","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/ng.2938","volume":"46","author":"G Wu","year":"2014","unstructured":"Wu, G. et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat. Genet. 46, 444\u2013450 (2014).","journal-title":"Nat. Genet."},{"key":"6_CR6","first-page":"153","volume":"19","author":"C Jones","year":"2016","unstructured":"Jones, C. et al. Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro Oncol. 19, 153\u2013161 (2016).","journal-title":"Neuro Oncol"},{"key":"6_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517\u2013528 (2015).","journal-title":"Lancet"},{"key":"6_CR8","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila, M. L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014).","journal-title":"Sci. Transl. Med."},{"key":"6_CR9","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"6_CR10","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2016-10-748772","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner, R. A. et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129, 3322\u20133331 (2017).","journal-title":"Blood"},{"key":"6_CR11","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375, 2561\u20132569 (2016).","journal-title":"N. Engl. J. Med."},{"key":"6_CR12","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","volume":"3","author":"N Ahmed","year":"2017","unstructured":"Ahmed, N. et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation Trial. JAMA Oncol. 3, 1094\u20131101 (2017).","journal-title":"JAMA Oncol"},{"issue":"399","key":"6_CR13","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"Donald M. O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke, D.M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9, eaaa0984 (2017).","journal-title":"Science Translational Medicine"},{"key":"6_CR14","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581\u2013590 (2015).","journal-title":"Nat. Med"},{"key":"6_CR15","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.1882","volume":"14","author":"MA Pule","year":"2008","unstructured":"Pule, M. A. et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14, 1264\u20131270 (2008).","journal-title":"Nat. Med"},{"key":"6_CR16","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","volume":"118","author":"CU Louis","year":"2011","unstructured":"Louis, C. U. et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118, 6050\u20136056 (2011).","journal-title":"Blood"},{"key":"6_CR17","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","volume":"25","author":"A Heczey","year":"2017","unstructured":"Heczey, A. et al. CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Mol. Ther. 25, 2214\u20132224 (2017).","journal-title":"Mol. Ther."},{"key":"6_CR18","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ccell.2017.03.002","volume":"31","author":"RG Majzner","year":"2017","unstructured":"Majzner, R. G., Heitzeneder, S. & Mackall, C. L. Harnessing the immunotherapy revolution for the treatment of childhood cancers. Cancer Cell 31, 476\u2013485 (2017).","journal-title":"Cancer Cell"},{"key":"6_CR19","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00401-012-0998-0","volume":"124","author":"DA Khuong-Quang","year":"2012","unstructured":"Khuong-Quang, D. A. et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 124, 439\u2013447 (2012).","journal-title":"Acta Neuropathol."},{"key":"6_CR20","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10833","volume":"482","author":"J Schwartzentruber","year":"2012","unstructured":"Schwartzentruber, J. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226\u2013231 (2012).","journal-title":"Nature"},{"key":"6_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152196","volume":"11","author":"S Thomas","year":"2016","unstructured":"Thomas, S., Straathof, K., Himoudi, N., Anderson, J. & Pule, M. An optimized GD2-targeting retroviral cassette for more potent and safer cellular therapy of neuroblastoma and other cancers. PLoS One 11, e0152196 (2016).","journal-title":"PLoS One"},{"key":"6_CR22","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1158\/2326-6066.CIR-15-0230","volume":"4","author":"AH Long","year":"2016","unstructured":"Long, A. H. et al. Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunol. Res. 4, 869\u2013880 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"6_CR23","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","volume":"363","author":"AL Yu","year":"2010","unstructured":"Yu, A. L. et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363, 1324\u20131334 (2010).","journal-title":"N. Engl. J. Med."},{"key":"6_CR24","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2217\/imt-2016-0021","volume":"8","author":"Z Perez Horta","year":"2016","unstructured":"Perez Horta, Z., Goldberg, J. L. & Sondel, P. M. Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy. Immunotherapy 8, 1097\u20131117 (2016).","journal-title":"Immunotherapy"},{"key":"6_CR25","doi-asserted-by":"publisher","first-page":"4892","DOI":"10.1158\/1078-0432.CCR-10-1507","volume":"16","author":"JJ Hong","year":"2010","unstructured":"Hong, J. J. et al. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin. Cancer Res. 16, 4892\u20134898 (2010).","journal-title":"Clin. Cancer Res."},{"key":"6_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/j.1471-4159.1965.tb04256.x","volume":"12","author":"K Suzuki","year":"1965","unstructured":"Suzuki, K. The pattern of mammalian brain gangliosides. II. Evaluation of the extraction procedures, postmortem changes and the effect of formalin preservation. J. Neurochem. 12, 629\u2013638 (1965).","journal-title":"J. Neurochem"},{"key":"6_CR27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11060-009-0038-7","volume":"97","author":"K Kramer","year":"2010","unstructured":"Kramer, K. et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J. Neurooncol. 97, 409\u2013418 (2010).","journal-title":"J. Neurooncol."},{"key":"6_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26754","volume":"65","author":"K Kramer","year":"2018","unstructured":"Kramer, K. et al. A phase II study of radioimmunotherapy with intraventricular 131 I-3F8 for medulloblastoma. Pediatr. Blood Cancer 65, e26754 (2018).","journal-title":"Pediatr. Blood Cancer"},{"key":"6_CR29","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.1073\/pnas.1101657108","volume":"108","author":"M Monje","year":"2011","unstructured":"Monje, M. et al. Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc. Natl Acad. Sci. USA 108, 4453\u20134458 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"6_CR30","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.cell.2017.07.016","volume":"170","author":"EY Qin","year":"2017","unstructured":"Qin, E. Y. et al. Neural precursor-derived pleiotrophin mediates subventricular zone invasion by glioma. Cell 170, 845\u2013859 (2017).","journal-title":"Cell"},{"key":"6_CR31","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nm.3855","volume":"21","author":"CS Grasso","year":"2015","unstructured":"Grasso, C. S. et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat. Med. 21, 555\u2013559 (2015).","journal-title":"Nat. Med"},{"key":"6_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24, 20\u201328 (2018).","journal-title":"Nat. Med"},{"key":"6_CR33","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1016\/j.ymthe.2017.06.008","volume":"25","author":"AJ Walker","year":"2017","unstructured":"Walker, A. J. et al. Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase. Mol. Ther. 25, 2189\u20132201 (2017).","journal-title":"Mol. Ther."},{"key":"6_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044219","volume":"7","author":"N Ali","year":"2012","unstructured":"Ali, N. et al. Xenogeneic graft-versus-host-disease in NOD-scid IL-2R\u03b3null mice display a T-effector memory phenotype. PLoS One 7, e44219 (2012).","journal-title":"PLoS One"},{"key":"6_CR35","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.ccell.2017.03.011","volume":"31","author":"S Nagaraja","year":"2017","unstructured":"Nagaraja, S. et al. Transcriptional dependencies in diffuse intrinsic pontine glioma. Cancer Cell 31, 635\u2013652 (2017).","journal-title":"Cancer Cell"},{"key":"6_CR36","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature14432","volume":"523","author":"A Louveau","year":"2015","unstructured":"Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337\u2013341 (2015).","journal-title":"Nature"},{"key":"6_CR37","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis, D. N. et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 131, 803\u2013820 (2016).","journal-title":"Acta Neuropathol."},{"key":"6_CR38","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412\u20137420 (2009).","journal-title":"Clin. Cancer Res."},{"key":"6_CR39","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust, J. et al. Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 7, 1404\u20131419 (2017).","journal-title":"Cancer Discov"},{"key":"6_CR40","volume":"7","author":"GL Lin","year":"2017","unstructured":"Lin, G. L. & Monje, M. A protocol for rapid post-mortem cell culture of diffuse intrinsic pontine glioma (DIPG). J. Vis. Exp. 7, e55360 (2017).","journal-title":"J. Vis. Exp."},{"key":"6_CR41","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1182\/blood-2014-11-612721","volume":"125","author":"RC Lynn","year":"2015","unstructured":"Lynn, R. C. et al. Targeting of folate receptor \u03b2 on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Blood 125, 3466\u20133476 (2015).","journal-title":"Blood"},{"key":"6_CR42","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","volume":"121","author":"W Haso","year":"2013","unstructured":"Haso, W. et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121, 1165\u20131174 (2013).","journal-title":"Blood"},{"key":"6_CR43","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00002371-199801000-00010","volume":"21","author":"G Sen","year":"1998","unstructured":"Sen, G., Chakraborty, M., Foon, K. A., Reisfeld, R. A. & Bhattacharya-Chatterjee, M. B. Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2. J. Immunother. 21, 75\u201383 (1998).","journal-title":"J. Immunother."},{"key":"6_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057838","volume":"8","author":"B Jena","year":"2013","unstructured":"Jena, B. et al. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLoS One 8, e57838 (2013).","journal-title":"PLoS One"},{"key":"6_CR45","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nbt.3290","volume":"33","author":"A Hendel","year":"2015","unstructured":"Hendel, A. et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat. Biotechnol. 33, 985\u2013989 (2015).","journal-title":"Nat. Biotechnol."},{"key":"6_CR46","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nbt.3198","volume":"33","author":"VT Chu","year":"2015","unstructured":"Chu, V. T. et al. Increasing the efficiency of homology-directed repair for CRISPR\u2013Cas9-induced precise gene editing in mammalian cells. Nat. Biotechnol. 33, 543\u2013548 (2015).","journal-title":"Nat. Biotechnol."},{"key":"6_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku936","volume":"42","author":"EK Brinkman","year":"2014","unstructured":"Brinkman, E. K., Chen, T., Amendola, M. & van Steensel, B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 42, e168 (2014).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41591-018-0006-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-018-0006-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-018-0006-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:55:49Z","timestamp":1684605349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-018-0006-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,16]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["6"],"URL":"https:\/\/doi.org\/10.1038\/s41591-018-0006-x","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,16]]},"assertion":[{"value":"5 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.L.M, M.M., R.G.M. and C.W.M. are inventors on a patent application for GD2-directed CAR use for H3-K27M DMG.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}